DRAK2 Antikörper
Kurzübersicht für DRAK2 Antikörper (ABIN7240802)
Target
Alle DRAK2 (STK17B) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Produktmerkmale
- Polyclonal Antibody
-
Aufreinigung
- Affinity purification
-
Immunogen
- Recombinant protein of human STK17B
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- IHC 1:50-1:200
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 0.5 mg/mL
-
Buffer
- PBS with 0.05 % sodium azide and 50 % glycerol, PH7.4
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Avoid freeze / thaw cycles.
-
-
- DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))
-
Andere Bezeichnung
- DRAK2
-
Hintergrund
- The full-lengthSTK17BcDNA clone encodes a deduced 372-amino acid protein with a molecular mass of 42.34 kD. The putative kinase domain is located at the N terminus and contains all 11 subdomains conserved among ser/thr kinases. STK17A andSTK17Bshare 59.7 % amino acid identity.Northern blot analysis revealed that STK17B was expressed in various tissues, such as heart, placenta, liver, and pancreas, as different-sized transcripts, presumably due to differences in the 3-prime untranslated region. Transient transfection of COS-7 cells showed that STK17B localized in nuclei. Phosphorylates myosin light chains. Acts as a positive regulator of apoptosis.
-
UniProt
- O94768
Target
-